NCT04305405 (TATE) is a Phase 3 clinical trial of Benralizumab in Severe Uncontrolled Asthma, sponsored by AstraZeneca.

Who is sponsoring NCT04305405?

NCT04305405 is sponsored by AstraZeneca.

What drugs are being tested in NCT04305405?

Interventions in NCT04305405: Benralizumab.

What condition does NCT04305405 study?

NCT04305405 studies Severe Uncontrolled Asthma.

Is NCT04305405 still recruiting?

NCT04305405 is currently completed. Last updated 18 May 2023.

Are results published for NCT04305405?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-05-18 · How we verify

NCT04305405: TATE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PK/PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma

Completed Phase 3 Results posted Last updated 18 May 2023

What this trial tests

Phase 3 trial testing Benralizumab in Severe Uncontrolled Asthma in 30 participants. Completed in 12 September 2022.

Timeline

21 November 2019

Primary endpoint
12 September 2022

12 September 2022

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	30
Start date	21 November 2019
Primary completion	12 September 2022
Estimated completion	12 September 2022
Sites	15 locations across Japan, United States

Drugs / interventions tested

Benralizumab (BENRALIZUMAB) — full drug profile →

Conditions studied

Severe Uncontrolled Asthma — all drugs for Severe Uncontrolled Asthma →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 6 to 14, any sex, with Severe Uncontrolled Asthma. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Clearance of Benralizumab Primary · Pre-dose on Days 0, 28, 56, 112, 168 and post-dose on Days 1, 7, 14, 84, 336; and at early discontinuation or withdrawal visit

Blood samples were collected to determine the clearance of benralizumab. This was an empirical Bayesian estimate (EBE) derived posthoc using population PK analysis.

Group	Value	95% CI
All Participants	0.156	± 0.0598

Area Under the Serum Concentration-Time Curve From Time Zero to Day 28 (AUC0-28) of Benralizumab Primary · Pre-dose on Days 0, 28 and post-dose on Days 1, 7, 14

Blood samples were collected to determine the AUC0-28 of benralizumab and it was calculated by linear up/log down trapezoidal summation. The PK parameters were estimated using non-compartmental analysis method.

Group	Value	95% CI
Benralizumab Dose 1, Aged 6-11 Years	36918.01	± 24.61
Benralizumab Dose 2, Aged 6-11 Years	75593.37	± 39.96
Benralizumab Dose 1, Aged 6-14 Years	36918.01	± 24.61
Benralizumab Dose 2, Aged 6-14 Years	73670.51	± 38.86

Maximum Observed Serum Concentration (Cmax) of Benralizumab Primary · Pre-dose on Days 0, 28, 56, 112, 168 and post-dose on Days 1, 7, 14, 84, 336; and at early discontinuation or withdrawal visit

Blood samples were collected to determine Cmax of benralizumab and it was directly calculated from the individual concentration-time curve. The PK parameters were estimated using non-compartmental analysis method.

Group	Value	95% CI
Benralizumab Dose 1, Aged 6-11 Years	1901.18	± 28.42
Benralizumab Dose 2, Aged 6-11 Years	3118.69	± 47.35
Benralizumab Dose 1, Aged 6-14 Years	1901.18	± 28.42
Benralizumab Dose 2, Aged 6-14 Years	3090.85	± 43.66

Terminal Phase Elimination Half-Life (t1/2) of Benralizumab Primary · Pre-dose on Days 0, 28, 56, 112, 168 and post-dose on Days 1, 7, 14, 84, 336; and at early discontinuation or withdrawal visit

Blood samples were collected to determine the t1/2 of benralizumab and it was calculated as natural logarithm of 2 \[ln(2)\]/terminal rate constant (λZ). This was an EBE derived posthoc using population PK analysis.

Group	Value	95% CI
All Participants	14.4	6.94 – 23.4

Time to Achieve Maximum Observed Serum Concentration (Tmax) of Benralizumab Primary · Pre-dose on Days 0, 28, 56, 112, 168 and post-dose on Days 1, 7, 14, 84, 336; and at early discontinuation or withdrawal visit

Blood samples were collected to determine the tmax of benralizumab and it was directly calculated from the individual concentration-time curve. The PK parameters were estimated using non-compartmental analysis method.

Group	Value	95% CI
Benralizumab Dose 1, Aged 6-11 Years	6.91	0.93 – 14.95
Benralizumab Dose 2, Aged 6-11 Years	7.26	1.10 – 14.01
Benralizumab Dose 1, Aged 6-14 Years	6.91	0.93 – 14.95
Benralizumab Dose 2, Aged 6-14 Years	7.94	1.10 – 14.01

Trough Concentration of Benralizumab at Week 16 (Ctrough16) Primary · Pre-dose on Day 112

Blood samples were collected to determine the trough concentration at Week 16, the lowest concentration reached by benralizumab before the next dose was administered. The PK parameters were estimated using non-compartmental analysis method.

Group	Value	95% CI
Benralizumab Dose 1, Aged 6-11 Years	142.42	± 256.34
Benralizumab Dose 2, Aged 6-11 Years	339.35	± 409.24
Benralizumab Dose 1, Aged 6-14 Years	142.42	± 256.34
Benralizumab Dose 2, Aged 6-14 Years	340.46	± 363.69

Change From Baseline in Peripheral Blood Eosinophil Count up to Week 48 Primary · Baseline (Day 0) and at Weeks 4, 8, 12, 16, 24 and 48

Blood samples were collected for determination of eosinophil count levels and were assessed in a central laboratory. Baseline is the last non-missing measurement prior to the first dose of study treatment.

Week 4

Group	Value	95% CI
Benralizumab Dose 1, Aged 6-11 Years	-447.3	± 283.76
Benralizumab Dose 2, Aged 6-11 Years	-436.9	± 408.28
Benralizumab Dose 1, Aged 6-14 Years	-447.3	± 283.76
Benralizumab Dose 2, Aged 6-14 Years	-455.3	± 385.58

Week 8

Group	Value	95% CI
Benralizumab Dose 1, Aged 6-11 Years	-445.3	± 276.20
Benralizumab Dose 2, Aged 6-11 Years	-453.8	± 396.03
Benralizumab Dose 1, Aged 6-14 Years	-445.3	± 276.20
Benralizumab Dose 2, Aged 6-14 Years	-470.7	± 374.25

Week 12

Group	Value	95% CI
Benralizumab Dose 1, Aged 6-11 Years	-443.3	± 286.85
Benralizumab Dose 2, Aged 6-11 Years	-455.8	± 419.32
Benralizumab Dose 1, Aged 6-14 Years	-443.3	± 286.85
Benralizumab Dose 2, Aged 6-14 Years	-472.9	± 393.49

Week 16

Group	Value	95% CI
Benralizumab Dose 1, Aged 6-11 Years	-446.7	± 279.12
Benralizumab Dose 2, Aged 6-11 Years	-402.7	± 384.61
Benralizumab Dose 1, Aged 6-14 Years	-446.7	± 279.12
Benralizumab Dose 2, Aged 6-14 Years	-430.0	± 378.68

Week 24

Group	Value	95% CI
Benralizumab Dose 1, Aged 6-11 Years	-354.2	± 323.99
Benralizumab Dose 2, Aged 6-11 Years	-436.9	± 405.90
Benralizumab Dose 1, Aged 6-14 Years	-354.2	± 323.99
Benralizumab Dose 2, Aged 6-14 Years	-457.9	± 397.77

Week 48

Group	Value	95% CI
Benralizumab Dose 1, Aged 6-11 Years	-434.0	± 286.15
Benralizumab Dose 2, Aged 6-11 Years	-453.8	± 392.78
Benralizumab Dose 1, Aged 6-14 Years	-434.0	± 286.15
Benralizumab Dose 2, Aged 6-14 Years	-474.3	± 385.04

Body Weight-Adjusted Clearance of Benralizumab Secondary · Pre-dose on Days 0, 28, 56, 112, 168 and post-dose on Days 1, 7, 14, 84, 336; and at early discontinuation or withdrawal visit

Blood samples were collected to determine the clearance of benralizumab. This was an EBE derived posthoc using population PK analysis.

Group	Value	95% CI
All Participants	0.00408	± 0.000764

Number of Participants With Anti-Drug Antibodies (ADA) Response to Benralizumab Secondary · Pre-dose at Baseline (Day 0), Weeks 8, 16 and 24 and post-dose at Week 48; and at early discontinuation or withdrawal visit

Blood samples were analyzed for the presence of ADAs for benralizumab. ADA prevalence: ADA positive (+ve) at any time point including baseline and/or post baseline. Treatment induced ADA+ve: ADA negative (-ve) at baseline and post-baseline ADA+ve. Treatment-boosted ADA+ve: baseline +ve ADA titer that was boosted by \>4-fold or higher-level following study drug administration. Treatment-emergent ADA+ve: either treatment-induced ADA+ve or treatment-boosted ADA+ve. Persistently +ve ADA: having at least 2 post-baseline ADA+ve assessments with at least 16 weeks (112 days) between the first and last

ADA prevalence

Group	Value	95% CI
Benralizumab Dose 1, Aged 6-11 Years	3
Benralizumab Dose 2, Aged 6-11 Years	1
Benralizumab Dose 1, Aged 6-14 Years	3
Benralizumab Dose 2, Aged 6-14 Years	1

Treatment-emergent ADA+ve

Group	Value	95% CI
Benralizumab Dose 1, Aged 6-11 Years	3
Benralizumab Dose 2, Aged 6-11 Years	1
Benralizumab Dose 1, Aged 6-14 Years	3
Benralizumab Dose 2, Aged 6-14 Years	1

Post-baseline ADA+ve

Group	Value	95% CI
Benralizumab Dose 1, Aged 6-11 Years	3
Benralizumab Dose 2, Aged 6-11 Years	1
Benralizumab Dose 1, Aged 6-14 Years	3
Benralizumab Dose 2, Aged 6-14 Years	1

Baseline and at least 1 post-baseline ADA+ve

Group	Value	95% CI
Benralizumab Dose 1, Aged 6-11 Years	0
Benralizumab Dose 2, Aged 6-11 Years	0
Benralizumab Dose 1, Aged 6-14 Years	0
Benralizumab Dose 2, Aged 6-14 Years	0

Only baseline ADA+ve

Group	Value	95% CI
Benralizumab Dose 1, Aged 6-11 Years	0
Benralizumab Dose 2, Aged 6-11 Years	0
Benralizumab Dose 1, Aged 6-14 Years	0
Benralizumab Dose 2, Aged 6-14 Years	0

Persistently ADA+ve

Group	Value	95% CI
Benralizumab Dose 1, Aged 6-11 Years	1
Benralizumab Dose 2, Aged 6-11 Years	0
Benralizumab Dose 1, Aged 6-14 Years	1
Benralizumab Dose 2, Aged 6-14 Years	0

Transiently ADA+ve

Group	Value	95% CI
Benralizumab Dose 1, Aged 6-11 Years	2
Benralizumab Dose 2, Aged 6-11 Years	1
Benralizumab Dose 1, Aged 6-14 Years	2
Benralizumab Dose 2, Aged 6-14 Years	1

nAb prevalence

Group	Value	95% CI
Benralizumab Dose 1, Aged 6-11 Years	3
Benralizumab Dose 2, Aged 6-11 Years	1
Benralizumab Dose 1, Aged 6-14 Years	3
Benralizumab Dose 2, Aged 6-14 Years	1

Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) up to Week 48 Secondary · Baseline (Day 0) and at Weeks 16 and 48

The FEV1 was defined as the volume of air exhaled from the lungs in the first second of a forced expiration and was measured by spirometry. Baseline is the last non-missing measurement with acceptable quality prior to the first dose of study treatment.

Week 16

Group	Value	95% CI
Benralizumab Dose 1, Aged 6-11 Years	-0.001	± 0.2434
Benralizumab Dose 2, Aged 6-11 Years	-0.119	± 0.2435
Benralizumab Dose 1, Aged 6-14 Years	-0.001	± 0.2434
Benralizumab Dose 2, Aged 6-14 Years	-0.165	± 0.2609

Week 48

Group	Value	95% CI
Benralizumab Dose 1, Aged 6-11 Years	0.003	± 0.3412
Benralizumab Dose 2, Aged 6-11 Years	0.425	± 0.4395
Benralizumab Dose 1, Aged 6-14 Years	0.003	± 0.3412
Benralizumab Dose 2, Aged 6-14 Years	0.428	± 0.4209

Change From Baseline in Interviewer-Administered Asthma Control Questionnaire (ACQ-IA) Score up to Week 48 Secondary · Baseline (Day 0), at Weeks 16 and 48; and at early discontinuation or withdrawal visit

The ACQ-IA is a 6-item assessment comprised of 6 patient-reported items. Participants were asked to record their experience with 5 symptoms (night-time waking, symptoms on waking, activity limitation, shortness of breath, and wheezing) and use of short-acting beta-2 agonist (SABA) over the previous week using a 7-point scale (0 = no impairment; and 6 = maximum impairment). The ACQ-IA score was calculated by the mean of the 7 equally weighted items. The score ranged from 0 (well controlled) to 6 (extremely poorly controlled). Higher scores indicated poor asthma control. Baseline is the last non

Week 16

Group	Value	95% CI
Benralizumab Dose 1, Aged 6-11 Years	-0.62	± 0.890
Benralizumab Dose 2, Aged 6-11 Years	-1.18	± 1.717
Benralizumab Dose 1, Aged 6-14 Years	-0.62	± 0.890
Benralizumab Dose 2, Aged 6-14 Years	-1.06	± 1.696

Week 48

Group	Value	95% CI
Benralizumab Dose 1, Aged 6-11 Years	-0.56	± 1.252
Benralizumab Dose 2, Aged 6-11 Years	-1.36	± 1.369
Benralizumab Dose 1, Aged 6-14 Years	-0.56	± 1.252
Benralizumab Dose 2, Aged 6-14 Years	-1.31	± 1.324

Number of Responders in Interviewer-Administered Patient Global Impression of Change (PGIC)-IA and Clinician Global Impression of Change (CGIC) Questionnaires Secondary · At Weeks 16 and 48; and at early discontinuation or withdrawal visit

The PGIC-IA and CGIC instruments were used for an overall evaluation of response to treatment, conducted separately by the Investigator and by the participant (administered by trained individuals to help the child understand the question and response options), using a 7-point scale: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; and 7=very much worse. The Investigator (clinician) and the participant were asked to rate the degree of change in the overall asthma status compared to the start of study treatment visit. Participants were de

PGIC-IA, Week 16, improved

Group	Value	95% CI
Benralizumab Dose 1, Aged 6-11 Years	13
Benralizumab Dose 2, Aged 6-11 Years	12
Benralizumab Dose 1, Aged 6-14 Years	13
Benralizumab Dose 2, Aged 6-14 Years	13

PGIC-IA, Week 16, much improved

Group	Value	95% CI
Benralizumab Dose 1, Aged 6-11 Years	10
Benralizumab Dose 2, Aged 6-11 Years	10
Benralizumab Dose 1, Aged 6-14 Years	10
Benralizumab Dose 2, Aged 6-14 Years	11

PGIC-IA, Week 16, very much improved

Group	Value	95% CI
Benralizumab Dose 1, Aged 6-11 Years	4
Benralizumab Dose 2, Aged 6-11 Years	8
Benralizumab Dose 1, Aged 6-14 Years	4
Benralizumab Dose 2, Aged 6-14 Years	9

PGIC-IA, Week 48, improved

Group	Value	95% CI
Benralizumab Dose 1, Aged 6-11 Years	13
Benralizumab Dose 2, Aged 6-11 Years	12
Benralizumab Dose 1, Aged 6-14 Years	13
Benralizumab Dose 2, Aged 6-14 Years	13

PGIC-IA, Week 48, much improved

Group	Value	95% CI
Benralizumab Dose 1, Aged 6-11 Years	9
Benralizumab Dose 2, Aged 6-11 Years	10
Benralizumab Dose 1, Aged 6-14 Years	9
Benralizumab Dose 2, Aged 6-14 Years	11

PGIC-IA, Week 48, very much improved

Group	Value	95% CI
Benralizumab Dose 1, Aged 6-11 Years	9
Benralizumab Dose 2, Aged 6-11 Years	9
Benralizumab Dose 1, Aged 6-14 Years	9
Benralizumab Dose 2, Aged 6-14 Years	10

CGIC, Week 16, improved

Group	Value	95% CI
Benralizumab Dose 1, Aged 6-11 Years	13
Benralizumab Dose 2, Aged 6-11 Years	11
Benralizumab Dose 1, Aged 6-14 Years	13
Benralizumab Dose 2, Aged 6-14 Years	12

CGIC, Week 16, much improved

Group	Value	95% CI
Benralizumab Dose 1, Aged 6-11 Years	8
Benralizumab Dose 2, Aged 6-11 Years	9
Benralizumab Dose 1, Aged 6-14 Years	8
Benralizumab Dose 2, Aged 6-14 Years	9

Adverse events — posted to ClinicalTrials.gov

Time frame: Treatment-emergent adverse events were collected from the start of study drug administration (Day 1) until end of follow-up, approximately up to Week 53. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Benralizumab Dose 1, Aged 6-11 Years

Serious: 1/15 (7%)

Deaths: 0/15

Benralizumab Dose 2, Aged 6-11 Years

Serious: 2/13 (15%)

Deaths: 0/13

Benralizumab Dose 1, Aged 6-14 Years

Serious: 1/15 (7%)

Deaths: 0/15

Benralizumab Dose 2, Aged 6-14 Years

Serious: 4/15 (27%)

Deaths: 0/15

Serious adverse events (2 terms)

Reaction	System	Benralizumab Dose 1, Aged …	Benralizumab Dose 2, Aged …	Benralizumab Dose 1, Aged …	Benralizumab Dose 2, Aged …
Asthma	Respiratory, thoracic and mediastinal disorders	—	—	—	—
Somatic symptom disorder	Psychiatric disorders	—	—	—	—

Other adverse events (56 terms — click to expand)

Reaction	System	Benralizumab Dose 1, Aged …	Benralizumab Dose 2, Aged …	Benralizumab Dose 1, Aged …	Benralizumab Dose 2, Aged …
Nasopharyngitis	Infections and infestations	—	—	—	—
Pyrexia	General disorders	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—
COVID-19	Infections and infestations	—	—	—	—
Pneumonia	Infections and infestations	—	—	—	—
Sinusitis	Infections and infestations	—	—	—	—
Viral upper respiratory tract infection	Infections and infestations	—	—	—	—
Pain in extremity	Musculoskeletal and connective tissue disorders	—	—	—	—
Headache	Nervous system disorders	—	—	—	—
Urticaria	Skin and subcutaneous tissue disorders	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—
Gastritis	Gastrointestinal disorders	—	—	—	—
Gastrooesophageal reflux disease	Gastrointestinal disorders	—	—	—	—
Chills	General disorders	—	—	—	—
Fatigue	General disorders	—	—	—	—
Injection site reaction	General disorders	—	—	—	—
Vaccination site pain	General disorders	—	—	—	—
Allergy to animal	Immune system disorders	—	—	—	—
Immunisation reaction	Immune system disorders	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—
Asymptomatic COVID-19	Infections and infestations	—	—	—	—
Bronchitis	Infections and infestations	—	—	—	—
Bronchitis bacterial	Infections and infestations	—	—	—	—
Gastroenteritis	Infections and infestations	—	—	—	—
Oral herpes	Infections and infestations	—	—	—	—
Pharyngitis	Infections and infestations	—	—	—	—
Pharyngitis streptococcal	Infections and infestations	—	—	—	—
Palpitations	Cardiac disorders	—	—	—	—
Skin candida	Infections and infestations	—	—	—	—
Streptococcal infection	Infections and infestations	—	—	—	—
Contusion	Injury, poisoning and procedural complications	—	—	—	—
Hand fracture	Injury, poisoning and procedural complications	—	—	—	—
Ligament rupture	Injury, poisoning and procedural complications	—	—	—	—
Road traffic accident	Injury, poisoning and procedural complications	—	—	—	—
Blood thyroid stimulating hormone decreased	Investigations	—	—	—	—
Occult blood positive	Investigations	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—
Depression	Psychiatric disorders	—	—	—	—

Most-reported serious reactions: Asthma, Somatic symptom disorder.

Data from ClinicalTrials.gov NCT04305405 adverse events section.

Sponsor's own description

This study will evaluate the PK, PD and long-term safety of Benralizumab administered subcutaneously in 30 children aged 6 to 11 years with severe eosinophilic asthma. Up to an additional 3 Japanese patients aged 12 to 14 years will be enrolled to meet local regulatory requirements.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Benralizumab in children with severe eosinophilic asthma: Pharmacokinetics and long-term safety (TATE study).
Wedner HJ, Fujisawa T, Guilbert TW, Ikeda M, et al · · 2024 · cited 24× · PMID 38491795 · DOI 10.1111/pai.14092
Biologics to Treat Severe Asthma in Children and Adolescents: A Practical Update.
Marseglia GL, Licari A, Tosca MA, Ciprandi G. · · 2020 · cited 2× · PMID 35921565 · DOI 10.1089/ped.2020.1212

Verify or expand the search:

Other trials of Benralizumab

Trials testing the same drug.

NCT07444567 — Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit Fr · Phase 3 · not yet recruiting
NCT06512883 — A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases · Phase 3 · recruiting
NCT06465485 — STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma · Phase 3 · active not recruiting
NCT06385236 — Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping · Phase 4 · recruiting
NCT05966584 — A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer · Phase 2 · terminated

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04305405 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 18 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04305405.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT04305405: TATE

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Serious adverse events (2 terms)

Sponsor's own description

Publications & conference data

Related trials

Other trials of Benralizumab

Other AstraZeneca trials

Verify against primary sources